Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Poseida Therapeutics (PSTX) has shared an announcement.
Poseida Therapeutics, Inc. has forged a significant collaboration with Xyphos Biosciences, granting them exclusive licenses to utilize Poseida’s intellectual property in developing innovative CAR-T therapies for solid tumors. With an upfront payment of $50 million from Xyphos and potential for an additional $550 million in milestones, plus royalties on net sales, this agreement promises to propel cancer treatment research forward. However, the partnership carries risks, such as potential early termination and reliance on Xyphos for development progress, underscoring the uncertain yet hopeful journey towards new therapeutic discoveries.
See more insights into PSTX stock on TipRanks’ Stock Analysis page.
